Study Evaluating the Efficacy and Safety of Etanercept and Methotrexate in Japanese Subjects With Rheumatoid Arthritis

• Status: Completed
• Trial end date: 2010-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to examine the effects of etanercept (10 mg and 25 mg) compared with methotrexate (up to 8 mg per week) on the slowing of joint destruction.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Etanercept; Methotrexate

Criteria

Inclusion Criteria:

• Must be Japanese and live in Japan

• Must be age 20 to 75 years

• Diagnosed less than or equal to 10 years from time of first visit

Exclusion Criteria:

• Anyone who has received etanercept or TNF-inhibitors such as infliximab or adalimumab in the past

• Patient with other rheumatic diseases or conditions that could predispose the patient to infection

• Pregnant or lactating women